Skip to content
PIL Logo

Adalat LA 60 mg prolonged-release tablets

Last Updated on eMC 13-Jun-2017 View document  | Bayer plc Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13-Jun-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 22-Aug-2016 and displayed until 13-Jun-2017

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 14-Aug-2015 and displayed until 22-Aug-2016

Reasons for adding or updating:

  • Change to section 6 - date of revision

Updated on 05-Feb-2014 and displayed until 14-Aug-2015

Reasons for adding or updating:

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 17-Apr-2012 and displayed until 05-Feb-2014

Reasons for adding or updating:

  • Change to date of revision

Updated on 03-Feb-2012 and displayed until 17-Apr-2012

Reasons for adding or updating:

  • Change to dosage and administration

Updated on 13-Aug-2010 and displayed until 03-Feb-2012

Reasons for adding or updating:

  • Change to date of revision
  • Change of contra-indications

Updated on 06-May-2010 and displayed until 13-Aug-2010

Reasons for adding or updating:

  • Extra statutory information

Updated on 07-Apr-2009 and displayed until 06-May-2010

Reasons for adding or updating:

  • Change to name of manufacturer

Updated on 28-Oct-2008 and displayed until 07-Apr-2009

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 30-Jun-2008 and displayed until 28-Oct-2008

Reasons for adding or updating:

  • Change to Marketing Authorisation Holder

Updated on 26-Feb-2008 and displayed until 30-Jun-2008

Reasons for adding or updating:

  • Correction of spelling/typing errors

Updated on 24-Jan-2008 and displayed until 26-Feb-2008

Reasons for adding or updating:

  • Change due to harmonisation of patient information leaflet

Updated on 25-Oct-2006 and displayed until 24-Jan-2008

Reasons for adding or updating:

  • Change to instructions about overdose
  • Change to date of revision

Updated on 28-Jul-2006 and displayed until 25-Oct-2006

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to instructions about missed dose
  • Change to date of revision

Updated on 15-Mar-2005 and displayed until 28-Jul-2006

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision

Updated on 20-Jan-2005 and displayed until 15-Mar-2005

Reasons for adding or updating:

  • Change of manufacturer

Updated on 23-Jan-2004 and displayed until 20-Jan-2005

Reasons for adding or updating:

  • Update to PIL

Updated on 05-Nov-2002 and displayed until 23-Jan-2004

Reasons for adding or updating:

  • Update to PIL

Updated on 25-Sep-2001 and displayed until 05-Nov-2002

Reasons for adding or updating:

  • Update to PIL

Updated on 27-Jun-2000 and displayed until 25-Sep-2001

Reasons for adding or updating:

  • No reasons supplied

Company contact details

Company image
Address

Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA

Fax

+44 (0)1635 563 393

Telephone

+44 (0)1635 563 000

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

nifedipine

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue